natgillin/translations-raw huggingface dataset:
The method according to any of the preceding claims, wherein said step e) is performed by several passes so as to first obtain a plurality of wavy grooves (101) and then said V-shaped races (7). 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da se navedeni korak e), izvodi u više prolaza na način da se, najprije, postigne veći broj valovitih brazdi (101), i potom utora u obliku slova V (7).
The use according to any one of the preceding claims, wherein the vegetal organic material is wood, wood residues, forest residues, mill residues, agricultural crops, agricultural residues, edible and/or non-edible plants or parts thereof, straw, garden wastes, aquatic plants, manure, organic municipal wastes and/or industrial organic wastes. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu je biljni organski materijal drvo, ostaci drveta, ostaci šume, ostaci iz mlina, poljoprivredni urodi, poljoprivredni ostaci, jestive i/ili nejestive biljke ili njihovi dijelovi, slama, vrtni otpad, vodene biljke, gnojivo, organski komunalni otpad i/ili industrijski organski otpad.
The use according to any one of the preceding claims, wherein the biomass comprises lignin, cellulose, hemicellulose, xylan, glucuronoxylan, arabinoxylan, glucomannan, xyloglucan, starch, sucrose, lactose, maltose, trehalose, glucose, xylose, mannose, arabinose, rhamnose, galactose and/or fructose. 
Uporaba u skladu s bilo kojim od prethodnih patentnih zahtjeva, pri čemu biomasa obuhvaća lignin, celulozu, hemicelulozu, ksilan, glukuronoksilan, arabinoksilan, glukomanan, ksiloglukan, škrob, sukrozu, laktozu, maltozu, trehalozu, glukozu, ksilozu, manozu, arabinozu, ramnozu, galaktozu i/ili fruktozu.
culturing and/or growing a Deinococcus bacterium in aerobic and/or anaerobic conditions, exposing a vegetal organic material to a composition comprising said Deinococcus bacterium or an extract thereof, and collecting ethanol produced. 
kultiviranje i/ili uzgoj bakterije Deinococcus u aerobnim i/ili anaerobnim uvjetima, izlaganje biljnog organskog materijala sastavu koji obuhvaća bakteriju Deinococcus ili njen ekstrakt, i sakupljanje proizvedenog etanola.
A firearm comprising a counteracting mobile mass configured to move in reaction to firing and to counter the recoil forces upon firing, the firearm comprising: 
Vatreno oružje obuhvaća neutralizirajuću pokretnu masu konfiguriranu da se pomiče kao reakcija na paljbu i da se suprotstavi silama izboja nakon paljbe, vatreno oružje obuhvaća:
a mobile mass (34) configured to pivot from a upward and cocked position under the barrel (21) to a lower position and having a surface to contact the mobile bolt (22) during its movement; 
pomičnu masu (34) konfiguriranu za rotiranje iz gornje i napete pozicije ispod spremnika (21) u donju poziciju i koja ima površinu za dodir s pomičnim zasunom (22) za vrijeme svog pomicanja;
The firearm of claim 1 or 2, wherein the mobile mass (34) has first and second angled surfaces, the first angled surface contacting a surface of the mobile bolt (22) immediately after firing. 
Vatreno oružje iz patentnog zahtjeva 1 ili 2, pri čemu pomična masa (34) ima prvu i drugu kutnu površinu, prva kutna površina dodiruje površinu pomičnog zasuna (22) odmah nakon paljbe.
The firearm of claim 1-6, wherein the pivoting movement of the mobile mass (34) is in the vertical plane containing the axix of the barrel (21) and is between about 10 to about 70 degrees of displacement from the upward position to the lower position. 
Vatreno oružje iz patentnih zahtjeva 1-6, pri čemu rotacijsko gibanje pomične mase (34) u vertikalnoj ravnini sadržava osi spremnika (21) i kreće se otprilike između 10 i 70 stupnjeva pomaka od gornje pozicije do donje pozicije.
The firearm of claim 1-7, wherein the first angled surface of the mobile mass (34) forms an angle of between about 10 degrees and about 70 degrees with respect to a line perpendicular to the longitudinal axis of the barrel (21). 
Vatreno oružje iz patentnih zahtjeva 1-7, pri čemu prva kutna površina pomične mase (34) tvori kut otprilike od 10 stupnjeva i otprilike od 70 stupnjeva u odnosu na liniju okomitu na uzdužnu os spremnika (21).
The firearm of claim 1 or 11, wherein the mobile mass (34) is linked to a spring and rod assembly whereby the spring is compressed as the mobile mass pivots downward. 
Vatreno oružje iz patentnog zahtjeva 1 ili 11, pri čemu je pomična masa (34) povezana sa sklopom opruge i štapa gdje je opruga stisnuta kad se pomična masa rotira prema dolje.
The firearm of claim 1 or 11-13, wherein the mobile mass (34) forms an angle of between about 10 and about 90 degrees with the longitudinal axis of the barrel (21) in its most lowered position. 
Vatreno oružje iz patentnog zahtjeva 1 ili 11-13, pri čemu pomična masa (34) tvori kut od približno 10 i 90 stupnjeva s uzdužnom osi spremnika (21) u svojoj najdonjoj poziciji.
Process for the production of a filled lollipop comprising the steps of: 
Postupak proizvodnje punjene lizalice, koji se sastoji od slijedećih koraka:
providing at least one mass of cooked candy composition; 
priprema najmanje jedne vrste ukuhane bombonske mase;
inserting sticks into the rope or into the pieces of rope through the candy region and at least partially into the filled hollow region; 
umetanje štapića u uže ili u izrezane komade užeta kroz masu bombona, i barem djelomično u područje napunjene šupljine;
Process as claimed in any one of the claims 1 to 5, wherein before the step d) the rope diameter is adjusted to the desired width by a series of rope seizers wheels. 
Postupak prema bilo kojem od zahtjeva od 1 do 5, naznačen time da se prije koraka d) promjer užeta podešava na željenu širinu pomoću uređaja s nizom kolotura za dimenzioniranje.
providing a high melting composition; covering the chocolate particles of step h) with the composition i). 
priprema smjese visoke točke taljenja; oblaganje čestica čokolade iz koraka h) smjesom i).
The compound of claim 3, wherein R6 is ethyl, propyl, isopropyl or isobutyl. 
Spoj u skladu s patentnim zahtjevom 3, naznačen time što R6 je etil, propil, izopropil ili izobutil.
The composition according to claim 12 further comprising a therapeutically effective amount of one or more antiviral agents. 
Sastav prema zahtjevu 12, naznačen time, da nadalje sadrži terapeutski učinkovitu količinu jednoga ili više antivirusnih sredstava.
The composition according to claim 13, wherein said antiviral agent is selected from: ribavirin and amantadine. 
Sastav prema zahtjevu 13, naznačen time, da je spomenuto antivirusno sredstvo odabrano od ribavirina i amantadina.
The composition according to claim 13 wherein the antiviral agent is an other anti-HCV agent. 
Sastav prema zahtjevu 13, naznačen time, da antivirusno sredstvo je jedno sljedeće anti-HCV-sredstvo.
The composition according to claim 15, wherein the other anti-HCV agent is another inhibitor of HCV polymerase. 
Sastav prema zahtjevu 15, naznačen time, da sljedeće anti-HCV-sredstvo je dodatni inhibitor HCV-polimeraze.
The composition according to claim 15, wherein the other anti-HCV agent is an inhibitor of HCV NS3 protease. 
Sastav prema zahtjevu 15, naznačen time, da sljedeće anti-HCV-sredstvo je inhibitor HCV NS3-proteaze.
A compound according to one or more of the claims 1 to 11, or a pharmaceutically acceptable salt or ester thereof, or a composition thereof, for use as an inhibitor of HCV polymerase. 
Spoj prema jednom ili više od zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, ili njegov ester, ili njegov sastav, naznačen time, da se upotrebljava kao inhibitor HCV-polimeraze.
A compound according to one or more of the claims 1 to 11, or a pharmaceutically acceptable salt or ester thereof, or a composition thereof, for use as an inhibitor of RNA dependent RNA polymerase activity of the enzyme NS5B, encoded by HCV. 
Spoj prema jednom ili više od zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, ili njegov ester, ili njegov sastav, naznačen time, da se upotrebljava kao inhibitor RNK-ovisne RNK-polimeraze djelovanja enzima NS5B, koja je kodirana HCV-om.
A compound according to one or more of the claims 1 to 11, or a pharmaceutically acceptable salt or ester thereof, or a composition thereof, for use as an inhibitor of HCV replication. 5 
Spoj prema jednom ili više od zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, ili njegov ester, ili njegov sastav, naznačen time, da se upotrebljava kao inhibitor HCV-replikacije.
A compound according to one or more of the claims 1 to 11, or a pharmaceutically acceptable salt or ester thereof, or a composition thereof, for use in the treatment or prevention of HCV infection in a mammal. 
Spoj prema jednom ili više od zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, ili njegov ester, ili njegov sastav, naznačen time, da se upotrebljava za liječenje ili prevenciju HCV-infekcije kod sisavaca.
A compound according to one or more of the claims 1 to 11, or a pharmaceutically acceptable salt or ester thereof, or a composition thereof, for use in the treatment or prevention of HCV infection in a mammal, in combination with another antiviral agent. 
Spoj prema jednom ili više od zahtjeva 1 do 11, ili njegova farmaceutski prihvatljiva sol, ili njegov ester, ili njegov sastav, naznačen time, da se upotrebljava za liječenje ili prevenciju HCV-infekcije kod sisavaca, u kombinaciji s dodatnim antivirusnim sredstvom.
A in-vitro method of inhibiting the RNA-dependent RNA polymerase activity of the enzyme NS5B, encoded by HCV, comprising exposing the enzyme NS5B to an effective amount of a compound according to one or more of the claims 1 to 11 under conditions where the RNA-dependent RNA polymerase activity of the enzyme NS5B is inhibited. 
Postupak in-vitro inhibicije RNK-ovisne RNK-polimeraze djelovanja enzima NS5B, koja je kodirana HCV-om, naznačen time, da obuhvaća izlaganje enzima NS5B učinkovitoj količini spoja prema jednom ili više od zahtjeva 1 do 11 pod uvjetima u kojima se inhibira RNK-ovisna RNK-polimeraza djelovanja enzima NS5B.
A in-vitro method of inhibiting HCV replication, comprising exposing a cell infected with HCV to an effective amount of a compound according to one or more of the claims 1 to 11 under conditions where replication of HCV is inhibited. 
Postupak in-vitro inhibicije HCV-replikacije, naznačen time, da obuhvaća izlaganje HCV-inficirane stanice učinkovitoj količini spoja prema jednom ili više od zahtjeva 1 do 11 pod uvjetima u kojima se inhibira HCV-replikacija.
A pharmaceutically acceptable salt or ester of a compound according to one or more of the claims 1 to 11, or a composition thereof, for use in a method of treating or preventing HCV infection in a mammal, comprising administering to the mammal an effective amount of the pharmaceutically acceptable salt or ester, or composition. 
Farmaceutski prihvatljiva sol ili ester od spoja prema jednom ili više od zahtjeva 1 do 11, ili njegov sastav, naznačen(a) time, da se upotrebljava u postupku liječenja ili prevencije HCV-infekcije kod sisavaca, koji obuhvaća primjenu na sisavcu učinkovite količine farmaceutski prihvatljive soli ili estera, ili sastava.
A pharmaceutically acceptable salt or ester of a compound according to one or more of the claims 1 to 11, or a composition thereof, for use in a method of treating or preventing HCV infection in a mammal, comprising administering to the mammal an effective amount of the pharmaceutically acceptable salt or ester, or composition, in combination with another antiviral agent. 
Farmaceutski prihvatljiva sol ili ester od spoja prema jednom ili više od zahtjeva 1 do 11, ili njegov sastav, naznačen(a) time, da se upotrebljava u postupku liječenja ili prevencije HCV-infekcije kod sisavaca, koji obuhvaća primjenu na sisavcu učinkovite količine farmaceutski prihvatljive soli ili estera, ili sastava, u kombinaciji s dodatnim antivirusnim sredstvom.
A device as claimed in claim 1, characterised in that the means (14) for moving the slide (10) and the means (28) for moving the milling cutter (22) consist of pneumatic cylinders. 
Uređaj u skladu s patentnim zahtjevom 1, naznačen time što sredstvo (14) za gibanje kliznika (10) i sredstvo (28) za gibanje glodala (22) se sastoji od pneumatskih cilindara.
Nucleic acid molecule comprising a nucleic acid sequence coding for the β chain of human follicle stimulating hormone (FSH), which is the coding region of the nucleic acid sequence according to SEQ ID No. 
Molekula nukleinske kiseline koja obuhvaća sekvencu nukleinskih kiselina koja kodira β lanac humanog folikulo stimulirajućeg hormona (FSH), a to je kodirajuća regija sekvence nukleinskih kiselina prema SEQ ID No.
Recombinant nucleic acid molecule comprising a first nucleic acid sequence according to claim 1 under the control of a promoter which is active in a host cell. 
Rekombinantna molekula nukleinske kiseline koja ima prvu sekvencu nukleinskih kiselina prema zahtjevu 1 pod kontrolom promotora koji je aktivan u stanici domaćinu.
Recombinant nucleic acid molecule according to claim 2, further comprising a second nucleic acid sequence coding for the a chain of human follicle stimulating hormone (FSH), which is selected from the group consisting of the coding region of the nucleic acid sequence according to SEQ ID No. 
Rekombinantna molekula nukleinske kiseline prema zahtjevu 2, dalje ima drugu sekvencu nukleinskih kiselina koja kodira a lanac humanog folikulo stimulirajućeg hormona (FSH), a izabire se iz grupe koja obuhvaća kodirajuću regiju sekvence nukleinskih kiselina prema SEQ ID No.
Recombinant nucleic acid molecule according to claim 2, further comprising a second nucleic acid sequence which is selected from the group consisting of the coding region of the nucleic acid sequence according to SEQ ID No. 
Rekombinantna molekula nukleinske kiseline prema zahtjevu 2, dalje ima drugu sekvencu nukleinskih kiselina koja se izabire iz grupe koja obuhvaća kodirajuću regiju sekvence nukleinskih kiselina prema SEQ ID No.
Recombinant nucleic acid molecule according to claim 4 or 5, wherein the second nucleic acid sequence is under the control of a separate promoter. 
Rekombinantna molekula nukleinske kiseline prema zahtjevu 3 ili 4, gdje je druga sekvenca nukleinskih kiselina pod kontrolom posebnog promotora.
Recombinant nucleic acid molecule according to any of claims 3 to 6, wherein the first nucleic acid sequence and/or the second nucleic acid sequence is under the control of a viral promoter. 
Rekombinantna molekula nukleinske kiseline prema bilo kojem od zahtjeva 2 do 5, gdje je prva sekvenca nukleinskih kiselina i/ili druga sekvenca nukleinskih kiselina pod kontrolom virusnog promotora.
Recombinant nucleic acid molecule according to claim 7, wherein the first nucleic acid sequence is under the control of an SV40 promoter. 
Rekombinantna molekula nukleinske kiseline prema zahtjevu 6, gdje je prva sekvenca nukleinskih kiselina pod kontrolom SV40 promotora.
Recombinant nucleic acid molecule according to claim 7, wherein the second nucleic acid sequence is under the control of a CMV promoter. 
Rekombinantna molekula nukleinske kiseline prema zahtjevu 6, gdje je druga sekvenca nukleinskih kiselina pod kontrolom CMV promotora.
Recombinant nucleic acid molecule according to any of claims 2 to 8, having the nucleic acid sequence as depicted in SEQ ID No. 
Rekombinantna molekula nukleinske kiseline prema bilo kojem od zahtjeva 2 do 8, ima sekvencu nukleinskih kiselina kako je prikazano za SEQ ID No.
Host cell according to claim 11 or 12, being a chinese hamster ovary (CHO) cell. 
Stanica domaćin prema zahtjevu 10 ili 11, koja je stanica jajnika kineskog hrčka (CHO).
Host cell containing a first recombinant nucleic acid molecule according to claim 2 and a second recombinant nucleic acid molecule comprising a nucleic acid sequence coding for the a chain of human follicle stimulating hormone (FSH), which is selected from the group consisting of the coding region of the nucleic acid sequence according to SEQ ID No. 
Stanica domaćin koja sadrži prvu rekombinantnu molekulu nukleinske kiseline prema zahtjevu 2 i drugu rekombinantnu molekulu nukleinske kiseline sa sekvencom nukleinskih kiselina koja kodira a lanac humanog folikulo stimulirajućeg hormona (FSH), a izabire se iz grupe koja obuhvaća kodirajuću regiju sekvence nukleinskih kiselina prema SEQ ID No.
harvesting the cell culture supernatant. 
ubiranje supernatanta stanične kulture.
Method for producing the host cell according claim 14, comprising transfecting cells in suspension culture under serum-free conditions with a first recombinant nucleic acid molecule according to claim 2 and a second recombinant nucleic acid molecule comprising a nucleic acid sequence coding for the a chain of human follicle stimulating hormone (FSH), which is selected from the group consisting of the coding region of the nucleic acid sequence according to SEQ ID No. 
Postupak proizvodnje stanica domaćina prema zahtjevu 14, obuhvaća transfekciju stanica, u kulturi suspenzije pod uvjetima bez prisutnosti seruma, prvom rekombinantnom molekulom nukleinske kiseline prema zahtjevu 2 i drugom rekombinantnom molekulom nukleinske kiseline koja obuhvaća sekvencu nukleinskih kiselina koja kodira a lanac humanog folikulo stimulirajućeg hormona (FSH), a izabire se iz grupe koja obuhvaća kodirajuću regiju sekvence nukleinskih kiselina prema SEQ ID No.
Use of a nucleic acid sequence according to SEQ ID No. 
Uporaba sekvence nukleinskih kiselina prema SEQ ID No.
1 or of both the nucleic acid sequences according to SEQ ID No. 
1 ili obje sekvence nukleinskih kiselina prema SEQ ID No.
1 and 2 for the in vitro production of human recombinant FSH. 
1 i 2 za in vitro proizvodnju humanog rekombinantnog FSH.
the first amount and second amount are each at least about 0.9 mg but is no more than about 1.5 mg; 
svaka od prve i druge količina je najmanje otprilike 0,9 mg, no najviše otprilike 1,5 mg;
ii) the first time period and second time period are less than two minutes; 
ii) prvi vremenski period i drugi vremenski period su manje od dvije minute;
iii) the first time period and the second time period are separated by an intermediate time period that is at least four hours but is less than twenty four hours; and iv) the child is at least 2 years of age but less than 12 years of age. 
iii) prvi vremenski period i drugi vremenski period su odvojeni vremenskim međuperiodom koji je najmanje 4 sata, no manje od 24 sata; i iv) dijete je staro najmanje 2 godine, no manje od 12 godina.
Olopatadine nasal spray as in any of claims 1-7 wherein the first amount and second amount of olopatadine are administered as part of a composition and the composition consists essentially of: 
Olopatadin nazalni sprej u skladu s bilo kojim od patentnih zahtjeva 1-7, naznačen time što se prvu i drugu količinu olopatadina primijenjuje kao dio pripravka, a pripravak se uglavnom sastoji od:
a phosphate salt in an amount equivalent to 0.2 - 0.8 % (w/v) dibasic sodium phosphate, wherein the phosphate salt selected from the group consisting of monobasic sodium phosphate; dibasic sodium phosphate; tribasic sodium phosphate; monobasic potassium phosphate; dibasic potassium phosphate; and tribasic potassium phosphate; 
fosfatne soli u količini ekvivalentnoj 0,2-0,8% (tež./vol.) dvobaznog natrijevog fosfata, gdje se fosfatnu sol bira iz skupine koju čine jednobazni natrijev fosfat; dvobazni natrijev fosfat; trobazni natrijev fosfat; jednobazni kalijev fosfat; dvobazni kalijev fosfat; te trobazni kalijev fosfat;
Olopatadine nasal spray as in any of claims 1-8 wherein the first amount and second amount of olopatadine are administered as part of a composition and the composition consists essentially of: % (w/v) olopatadine free base or an equivalent amount of a pharmaceutically acceptable salt of olopatadine; 
Olopatadin nazalni sprej u skladu s bilo kojim od patentnih zahtjeva 1-8, naznačen time što se prvu i drugu količinu olopatadina primijenjuje kao dio pripravka, a pripravak se uglavnom sastoji od: 0,6% (tež./vol.) slobodne baze olopatadina ili ekvivalentne količine farmaceutski prihvatljive soli olopatadina;
a nasal sprayer containing an olopatadine nasal spray according to claim 1; and instructions for administration of the nasal spray to a child provided with the nasal sprayer wherein administration of the nasal spray according to the instructions would result in administration of olopatadine in accordance with the following regimen: 
nazalni sprej koji sadrži olopatadin nazalni sprej u skladu s patentnim zahtjevom 1; i upute o primjeni nazalnog spreja kod djeteta provided s nazalnim sprejem, gdje će primjena nazalnog spreja prema uputama rezultirati primjenom olopatadina prema sljedećem režimu:
administration of a first amount of olopatadine to nostrils of a child during a first time period wherein the first time period is less than two minutes and wherein the child is at least 2 years of age but less than 12 years of age and wherein the first amount is at least about 0.9 mg but is no more than about 1.5 mg; and ii) administration of a second amount of olopatadine to the nostrils of the child during a second time period wherein the second time period is less than two minutes and wherein the first time period and the second time period are separated by an intermediate time period that is at least four hours but is less than twenty four hours and the second time period is less than two minutes and wherein the second amount is at least about 0.9 mg but is no more than about 1.5 mg. 
primjena prve količine olopatadina u nosnice djeteta tijekom prvog vremenskog perioda, gdje je prvi vremenski period manje od dvije minute, a dijete je staro najmanje 2 godine, no manje od 12 godina, te gdje je prva količina najmanje otprilike 0,9 mg, no najviše otprilike 1,5 mg; i ii) primjena druge količine olopatadina u nosnice djeteta tijekom drugog vremenskog perioda, gdje je drugi vremenski period manje od dvije minute, a prvi vremenski period i drugi vremenski period su odvojeni vremenskim međuperiodom koji je najmanje 4 sata, no manje od 24 sata, gdje je drugi vremenski period je manje od dvije minute, a druga količina je najmanje otprilike 0,9 mg, no najviše otprilike 1,5 mg.
A product as in claim 10 or 11 wherein the first amount and second amount are both at least about 1.1 mg. 
Proizvod u skladu s patentnim zahtjevom 10 ili 11, naznačen time što su i prva i druga količina najmanje otprilike 1,1 mg.
encoding Physical Layer Pipe, PLP, data for carrying at least one service; encoding Layer1, L1, signaling data for signaling the PLP data, wherein the encoding L1 signaling data further comprises; 
kodiranje podataka cijevi fizičke razine, PLP, za prijenos najmanje jednog servisa i signalnog podatka razine 1, L1, za signaliziranje PLP podataka; stvaranje podatkovnih rezova uključujući kodirane PLP podatke;
means (308-1) for selectively time-interleaving the encoded L1 signaling data by a row-column twisted fashion, wherein the row-column twisted fashion comprises input L1 signaling data cells serially written into an interleaving memory in a diagonal direction, and serially read out row-wise, without considering pilot positions, and outputting an L1, Time Interleaving, TI, block; 
sredstvo (308-1) za selektivno umetanje vremena kodiranih L1 signalnih podataka na način prelamanja redova-stupaca, pri čemu način prelamanja redova-stupaca obuhvaća unos u podatkovne stanice signalnih podataka L1 serijski upisanih u memoriju umetanja u dijagonalnom smjeru, i serijsko očitavanje u smjeru redova, bez razmatranja pozicija pilota, i izlaz L1, bloka umetanje vremena, TI;